RxDoctor Payments Data

Ronald Pang, MD

Gastroenterology · Honolulu, HINPI 1801996673

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 67.3% of it on its own, with 9 other manufacturers making up the rest. That places this record below the midpoint for gastroenterology clinicians in HI, where the typical reported total is $1,198.

$1,556in general payments, 2019–2025

Across 79 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Ironwood Pharmaceuticals, Inc$127
  • Covidien LP$92
  • Micro-tech Endoscopy USA, Inc.$85
  • Johnson & Johnson$74
  • Ardelyx, Inc.$42
  • plus $88 from 4 others

What the payments were for

  • Food & beverage$1,556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,556 in reported general payments places this provider in the 50th percentile of 71 gastroenterology providers in Hawaii.

See all gastroenterology providers in Hawaii

Medicare billing

Part B allowed, 2024
$28,748
Medicare patients
48
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide22$31,170
Famotidine78$1,925
Esomeprazole Magnesium26$1,738
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl100$1,533
Omeprazole29$900
Lansoprazole15$411
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl14$189
Metoclopramide Hcl19$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,048$31,17022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 71 gastroenterology providers in Hawaii.

Other gastroenterology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →